이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

활동성 특발성 염증성 근육병증이 있는 피험자에서 CABA-201의 안전성과 효능을 평가하기 위한 공개 라벨 연구

2026년 11월 12일 업데이트: Cabaletta Bio

활동성 특발성 염증성 근육병증 환자를 대상으로 자가 CD19 특이적 키메라 항원 수용체 T 세포(CABA-201)의 안전성과 효능을 평가하기 위한 1/2상 공개 라벨 연구

RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.

연구 유형

중재적

등록 (추정된)

74

단계

  • 2 단계
  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Göttingen, 독일, 37075
        • 아직 모집하지 않음
        • Universitätsmedizin Göttingen - Accepting Adult Patients
        • 연락하다:
        • 수석 연구원:
          • Dr. Jana Zschüntzsch
    • California
      • Orange, California, 미국, 92868
        • 모병
        • University of California Irvine - Accepting Adult Patients
        • 수석 연구원:
          • Tahseen Mozaffar, MD
        • 연락하다:
      • San Francisco, California, 미국, 94158
        • 모병
        • University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients
        • 연락하다:
        • 수석 연구원:
          • Susan Kim, MD, MMSc
    • Colorado
      • Aurora, Colorado, 미국, 80046
        • 모병
        • Children's Hospital Colorado - Accepting Juvenile Patients
        • 수석 연구원:
          • Dr. Kentaro Yomogida, MD
        • 연락하다:
    • Florida
      • Jacksonville, Florida, 미국, 32224
        • 모병
        • Mayo Clinic Florida - Accepting Adult Patients
        • 연락하다:
      • St. Petersburg, Florida, 미국, 33701
        • 모병
        • Johns Hopkins All Children's Hospital - Accepting Juvenile Patients
        • 수석 연구원:
          • Natalie Booth, DO
        • 연락하다:
    • Georgia
      • Atlanta, Georgia, 미국, 30032
        • 모병
        • Emory University - Accepting Adult Patients
        • 연락하다:
        • 수석 연구원:
          • Prateek Chandrashekar Gandiga, MD, FACP
      • Atlanta, Georgia, 미국, 30029
        • 모병
        • Children's Healthcare of Atlanta - Accepting Juvenile Patients
        • 수석 연구원:
          • Shanmuganathan Chandrakasan, MD
        • 연락하다:
    • Illinois
      • Chicago, Illinois, 미국, 60611
        • 모병
        • Northwestern Memorial Hospital - Accepting Adult Patients
        • 수석 연구원:
          • Dr. George Georges, MD
        • 연락하다:
      • Chicago, Illinois, 미국, 60637
      • Chicago, Illinois, 미국, 60611
        • 모병
        • Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients
        • 연락하다:
        • 수석 연구원:
          • Pooja N. Patel, DO
    • Kansas
      • Kansas City, Kansas, 미국, 66160
        • 모병
        • University of Kansas Medical Center - Accepting Adult Patients
        • 연락하다:
    • Maryland
      • Bethesda, Maryland, 미국, 20892
        • 모병
        • National Institutes of Health - Accepting Adult and Juvenile Patients
        • 연락하다:
        • 수석 연구원:
          • Andrew Mammen, M.D., Ph.D.
    • Massachusetts
      • Boston, Massachusetts, 미국, 02115
        • 모병
        • Boston Children's Hospital - Accepting Young Adults and Juvenile Patients
        • 수석 연구원:
          • Susan Prockop, MD
        • 연락하다:
    • Michigan
      • Ann Arbor, Michigan, 미국, 48105
        • 모병
        • University of Michigan - Accepting Young Adult and Juvenile Patients
        • 연락하다:
        • 수석 연구원:
          • Dr. Jennifer Agrusa, MD
    • Minnesota
      • Rochester, Minnesota, 미국, 55902
        • 모병
        • Mayo Clinic - Accepting Adult Patients
        • 연락하다:
    • New York
      • New York, New York, 미국, 10021
        • 모병
        • Hospital for Special Surgery - Accepting Adult and Juvenile Patients
        • 연락하다:
        • 수석 연구원:
          • David R. Fernandez, MD, PhD
      • New York, New York, 미국, 10021
        • 모병
        • Memorial Sloan Kettering Cancer Center - Accepting Adult and Juvenile Patients
        • 수석 연구원:
          • Jae Park, MD
        • 연락하다:
      • The Bronx, New York, 미국, 10467
        • 모병
        • Children's Hospital at Montefiore - Accepting Young Adult and Juvenile Patients
        • 연락하다:
        • 수석 연구원:
          • Dr. Dawn Wahezi, MD, MS
    • North Carolina
      • Chapel Hill, North Carolina, 미국, 27599
        • 모병
        • University of North Carolina at Chapel Hill - Accepting Adult Patients
        • 수석 연구원:
          • Saira Sheikh, MD
        • 연락하다:
      • Durham, North Carolina, 미국, 27710
        • 모병
        • Duke University Medical Center - Accepting Young Adults and Juvenile Patients
        • 수석 연구원:
          • Kaveh Ardalan, MD, MS
        • 연락하다:
    • Oregon
      • Portland, Oregon, 미국, 97239
        • 모병
        • Oregon Health & Science University - Accepting Adult Patients
        • 연락하다:
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19104
        • 모병
        • Children's Hospital of Philadelphia - Accepting Young Adult and Juvenile Patients
        • 연락하다:
        • 수석 연구원:
          • Dr. Caitlin Elgarten, MD, MSCE
      • Pittsburgh, Pennsylvania, 미국, 15261
        • 모병
        • UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients
        • 연락하다:
        • 수석 연구원:
          • Jeremy Tilstra, MD
      • Pittsburgh, Pennsylvania, 미국, 15224
        • 모병
        • UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients
        • 연락하다:
        • 수석 연구원:
          • Kathryn Torok, MD
    • Tennessee
      • Nashville, Tennessee, 미국, 37232
        • 모병
        • Vanderbilt University Medical Center - Accepting Adult Patients
        • 연락하다:
    • Texas
      • Dallas, Texas, 미국, 75390
        • 모병
        • University of Texas Southwestern Medical Center - Accepting Juvenile Patients
        • 수석 연구원:
          • Samuel John, MD
        • 연락하다:
      • Houston, Texas, 미국, 77030
        • 모병
        • Houston Methodist Hospital - Accepting Adult Patients
        • 연락하다:
      • Houston, Texas, 미국, 77030
        • 모병
        • University of Texas MD Anderson Cancer Center - Accepting Adult Patients
        • 수석 연구원:
          • Huifang (Linda) Lu, MD
        • 연락하다:
    • Utah
      • Salt Lake City, Utah, 미국, 84113
        • 모병
        • Primary Children's Hospital/University of Utah - Accepting Juvenile Patients
        • 연락하다:
        • 수석 연구원:
          • Aimee Ogden Hersh, MD
    • Washington
      • Seattle, Washington, 미국, 98105
        • 모병
        • Seattle Children's Research Institute - Accepting Juvenile Patients
        • 연락하다:
        • 수석 연구원:
          • Dr. Susan Shenoi, MD, MS
    • Wisconsin
      • Milwaukee, Wisconsin, 미국, 53226
        • 아직 모집하지 않음
        • Children's Wisconsin Pediatric Rheumatology -Accepting Young Adult and Juvenile Patients
        • 수석 연구원:
          • Sara Sabbagh, DO
        • 연락하다:
          • Erin Hammelev - Research Coordinator
          • 전화번호: 414-337-7064
          • 이메일: ehammele@mcw.edu
      • London, 영국, WC1N 3BG
        • 모병
        • University College London Hospitals NHS Foundation Trust - Accepting Adult Patients
        • 연락하다:
        • 수석 연구원:
          • Dr. Pedro Machado, FRCP, PhD
      • London, 영국, SE5 9RS
        • 모병
        • Kings College Hospital NHS Foundation Trust - Accepting Adult Patients
        • 연락하다:
        • 수석 연구원:
          • Patrick Gordon, PhD, FRCP, MBBS
      • London, 영국, WC1N 3JH
        • 모병
        • Great Ormond Street Hospital for Children NHS Foundation Trust - Accepting Juvenile Patients
        • 연락하다:
        • 수석 연구원:
          • Professor Despina Eleftheriou
      • Manchester, 영국, M13 9WL
        • 모병
        • Manchester Royal Infirmary - Accepting Adult Patients
        • 연락하다:
        • 수석 연구원:
          • Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
      • Salford, 영국, M6 8HD
        • 모병
        • Salford Royal Hospital - Accepting Adult Patients
        • 연락하다:
        • 수석 연구원:
          • Hector Chinoy, PhD, FRCP, MSc, BMBS, BMedSci
      • Roma, 이탈리아, 00165
        • 모병
        • Ospedale Pediatrico Bambino Gesù - Accepting Young Adult and Juvenile Patients
        • 연락하다:
        • 수석 연구원:
          • Professor Franco Locatelli

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

6년 (어린이, 성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Adult Cohorts

Inclusion Criteria:

  • Age ≥18 and ≤75
  • A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
  • Diagnosis of DM, ASyS, or IMNM
  • Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
  • Presence of muscle weakness

Other protocol-defined criteria apply.

Exclusion Criteria:

  • Contraindication to leukapheresis
  • History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
  • Active infection requiring medical intervention at screening
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections
  • Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
  • Significant lung or cardiac impairment
  • Previous CAR T cell therapy
  • Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant

Other protocol-defined criteria apply.

Juvenile Cohort

Inclusion Criteria:

  • Age ≥6 and ≤17 years at enrollment
  • A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
  • Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated muscle enzymes, DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography

Other protocol-defined criteria apply.

Exclusion Criteria:

  • Contraindication to leukapheresis
  • History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
  • Active infection requiring medical intervention at screening
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.
  • Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
  • Significant lung or cardiac impairment
  • Previous CAR T cell therapy
  • Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant

Other protocol-defined criteria apply.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: CABA-201 Phase 1/2

DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM.

ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with ASyS.

IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM.

JIIM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with JIIM.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

다른 이름들:
  • RESE-CEL
  • 재 체사 유전자 autoleucel
실험적: CABA-201 Phase 2b - Sub-study 1

Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM and ASyS.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

다른 이름들:
  • RESE-CEL
  • 재 체사 유전자 autoleucel
실험적: CABA-201 Phase 2b - Sub-study 2

Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

다른 이름들:
  • RESE-CEL
  • 재 체사 유전자 autoleucel

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Phase 1/2: Incidence and severity of adverse events (AEs)
기간: Up to 28 days after CABA-201 infusion

Incidence and severity of AEs

Up to 28 days after CABA-201 infusion
Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids
기간: Within 16 weeks

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Within 16 weeks
Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids
기간: Within 24 weeks

≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Within 24 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
Incidence of adverse events and laboratory abnormalities
기간: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Incidence and severity of AEs, including changes in laboratory values and vital signs

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Pharmacodynamics (PD)
기간: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Levels of B cells in the blood

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Pharmacokinetics (PK)
기간: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Levels of CABA-201-positive T cells in the blood

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Change in disease-related biomarkers of muscle inflammation
기간: Up to 156 weeks (Phase 1/2)

Levels of muscle enzymes (CK, LDH, AST, ALT, and aldolase) in serum

Up to 156 weeks (Phase 1/2)
Change in autoantibody-related biomarkers
기간: Up to 156 weeks (Phase 1/2)

Levels of autoantibodies from the Myositis-Specific Autoantibody Panel (e.g., MDA-5, Jo-1, and HMGCR) in the serum

Up to 156 weeks (Phase 1/2)
Proportion of DM subjects achieving at least a moderate TIS without any immunomodulatory medications and no or low dose of steroids
기간: Week 16 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 16 (Sub-study 1)
Mean change from baseline on the MMT-8 in subjects with DM and ASyS without any immunomodulatory medications and no or low dose of steroids
기간: Week 16 (Sub-study 1)

MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength

Week 16 (Sub-study 1)
Proportion of DM and ASyS subjects achieving a major TIS response without any immunomodulatory medications and no or low dose of steroids
기간: Week 16 (Sub-study 1)

≥60 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 16 (Sub-study 1)
Proportion of subjects with DM & ASyS achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
기간: Week 52 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 1)
Proportion of subjects with DM achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
기간: Week 52 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 1)
Mean change from baseline on the MMT-8 in subjects with IMNM without any immunomodulatory medications and no or low dose of steroids
기간: Week 24 (Sub-study 2)

MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength

Week 24 (Sub-study 2)
Proportion of subjects with IMNM achieving at least minimal TIS response without immunomodulatory medications and no or low dose of steroids
기간: Week 52 (Sub-study 2)

≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 2)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 의자: Medical Director, Cabaletta Bio

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 12월 20일

기본 완료 (추정된)

2028년 7월 1일

연구 완료 (추정된)

2028년 7월 1일

연구 등록 날짜

최초 제출

2023년 11월 16일

QC 기준을 충족하는 최초 제출

2023년 11월 30일

처음 게시됨 (실제)

2023년 12월 4일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 13일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 12일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .